Royal Bank of Canada Lowers Inovio Pharmaceuticals Price Target

Inovio Pharmaceuticals (NASDAQ:INO) has recently experienced a downgrade in its price target from Royal Bank of Canada. In a research note released on Wednesday, analysts from the bank reduced the price objective for Inovio from $6.00 to $5.00. This update comes alongside a designation of a "sector perform" rating for the biopharmaceutical company.

The new price target suggests a potential upside of 147.77% based on the stock's previous closing price. This is notable, especially considering the current market dynamics surrounding the biopharmaceutical industry.

Inovio Pharmaceuticals has received attention from various research firms recently. HC Wainwright reiterated a "neutral" rating with a price objective of $3.00 earlier on the same day. Meanwhile, JMP Securities maintained a "market outperform" rating with a significantly higher price target set at $18.00 as of January 10.

Overall, analysts have varied outlooks for Inovio. There is currently one sell rating, two hold ratings, and three buy ratings on the stock. According to data from MarketBeat.com, the consensus rating for Inovio Pharmaceuticals stands at "Hold," with an average target price of approximately $12.20.

Inovio Pharmaceuticals Stock Analysis

During midday trading on Wednesday, Inovio Pharmaceuticals' stock declined by $0.08, reaching a price of $2.02 per share. The trading volume for the day was recorded at 261,914 shares, which is lower than the average volume of 539,855 shares. The stock has a 50-day simple moving average of $2.05 and a 200-day simple moving average of $3.77. Over the past year, Inovio's stock has experienced a low of $1.74 and a high of $14.75. Inovio Pharmaceuticals currently has a market capitalization of $52.67 million and a price-to-earnings ratio of -0.96, with a beta of 0.92.

Institutional Holdings

Institutional investors have been actively trading Inovio Pharmaceuticals’ shares, with some recent changes in their holdings. For instance, Alpine Global Management LLC acquired a new stake in the company during the fourth quarter, valued at approximately $31,000. BNP Paribas Financial Markets increased its stake by 177.0%, now owning 5,681 shares worth about $33,000 after adding 3,630 shares. Other notable changes include Bank of Montreal Can and Boothbay Fund Management LLC, which both established new positions in the fourth quarter.

Overall, institutional investors hold around 26.79% of Inovio Pharmaceuticals' stock, reflecting growing interest in the company despite market fluctuations.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the innovation, development, and commercialization of DNA medicines that target diseases such as human papillomavirus (HPV), cancer, and various infectious diseases. The company employs a DNA medicines platform utilizing SynCon technology to optimize DNA sequences for target antigens, along with CELLECTRA smart devices for effective delivery of DNA plasmids.

Inovio, Pharmaceuticals, Stock